Welgene Biotech Co.,Ltd. (6661.TWO)

TWD 20.0

(-9.91%)

Total Liabilities Summary of Welgene Biotech Co.,Ltd.

Welgene Biotech Co.,Ltd.'s latest annual total liabilities in 2023 was 247.89 Million TWD , up 88.14% from previous year.
Welgene Biotech Co.,Ltd.'s latest quarterly total liabilities in 2024 Q2 was 232.78 Million TWD , up 4.27% from previous quarter.
Welgene Biotech Co.,Ltd. reported annual total liabilities of 131.76 Million TWD in 2022, up 15.1% from previous year.
Welgene Biotech Co.,Ltd. reported annual total liabilities of 114.47 Million TWD in 2021, up 6.44% from previous year.
Welgene Biotech Co.,Ltd. reported quarterly total liabilities of 232.78 Million TWD for 2024 Q2, up 4.27% from previous quarter.
Welgene Biotech Co.,Ltd. reported quarterly total liabilities of 247.89 Million TWD for 2023 FY, up 88.14% from previous quarter.

Annual Total Liabilities Chart of Welgene Biotech Co.,Ltd. (2023 - 2014)

Historical Annual Total Liabilities of Welgene Biotech Co.,Ltd. (2023 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2023	247.89 Million TWD	88.14%
2022	131.76 Million TWD	15.1%
2021	114.47 Million TWD	6.44%
2020	107.54 Million TWD	-37.29%
2019	171.49 Million TWD	48.11%
2018	115.78 Million TWD	31.02%
2017	88.37 Million TWD	22.24%
2016	72.29 Million TWD	-11.62%
2015	81.79 Million TWD	-24.43%
2014	108.24 Million TWD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	223.25 Million TWD	-9.94%
2024 Q2	232.78 Million TWD	4.27%
2023 FY	247.89 Million TWD	88.14%
2023 Q3	202.34 Million TWD	-9.19%
2023 Q4	247.89 Million TWD	22.51%
2023 Q1	141.6 Million TWD	7.47%
2023 Q2	222.82 Million TWD	57.36%
2022 Q3	75.57 Million TWD	12.9%
2022 Q2	66.93 Million TWD	-36.6%
2022 Q1	105.58 Million TWD	-7.76%
2022 FY	131.76 Million TWD	15.1%
2022 Q4	131.76 Million TWD	74.34%
2021 Q1	89.25 Million TWD	-17.01%
2021 Q3	70.54 Million TWD	-24.1%
2021 Q4	114.47 Million TWD	62.27%
2021 FY	114.47 Million TWD	6.44%
2021 Q2	92.94 Million TWD	4.14%
2020 Q4	107.54 Million TWD	-7.37%
2020 FY	107.54 Million TWD	-37.29%
2020 Q3	116.1 Million TWD	-23.26%
2020 Q2	151.29 Million TWD	0.0%
2020 Q1	- TWD	-100.0%
2019 Q2	139.85 Million TWD	0.33%
2019 Q1	139.4 Million TWD	20.39%
2019 FY	171.49 Million TWD	48.11%
2019 Q4	171.49 Million TWD	0.0%
2018 Q4	115.78 Million TWD	0.35%
2018 FY	115.78 Million TWD	31.02%
2018 Q1	78.65 Million TWD	-10.99%
2018 Q2	78.65 Million TWD	0.0%
2018 Q3	115.38 Million TWD	46.69%
2017 Q2	69.36 Million TWD	0.0%
2017 Q1	69.36 Million TWD	-4.05%
2017 Q4	88.37 Million TWD	0.0%
2017 Q3	88.37 Million TWD	27.4%
2017 FY	88.37 Million TWD	22.24%
2016 FY	72.29 Million TWD	-11.62%
2016 Q4	72.29 Million TWD	0.0%
2016 Q3	72.29 Million TWD	0.0%
2015 FY	81.79 Million TWD	-24.43%
2014 FY	108.24 Million TWD	0.0%

Peer Total Liabilities Comparison of Welgene Biotech Co.,Ltd.

Name	Total Liabilities	Total Liabilities Difference
BIONET Corp.	626.46 Million TWD	60.43%
DIVA Laboratories, Ltd.	210.93 Million TWD	-17.524%
Genetics Generation Advancement Corp.	164.9 Million TWD	-50.324%
Puriblood Medical Co., Ltd.	84.35 Million TWD	-193.884%
TFBS Bioscience Inc.	187.43 Million TWD	-32.255%